vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.9M, roughly 1.0× Opus Genetics, Inc.).
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
CTXR vs IRD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $3.9M |
| Net Profit | $-9.4M | — |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | — |
| Net Margin | -238.2% | — |
| Revenue YoY | — | -10.2% |
| Net Profit YoY | 8.6% | 53.0% |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $3.9M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.4M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-9.4M | — | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-8.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-7.5M | ||
| Q2 24 | — | $-7.8M | ||
| Q1 24 | — | $-7.1M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -228.7% | — | ||
| Q3 25 | — | -269.9% | ||
| Q2 25 | — | -309.0% | ||
| Q1 25 | — | -227.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -207.1% | ||
| Q2 24 | — | -748.9% | ||
| Q1 24 | — | -450.5% |
| Q4 25 | -238.2% | — | ||
| Q3 25 | — | -566.9% | ||
| Q2 25 | — | -257.5% | ||
| Q1 25 | — | -187.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -194.6% | ||
| Q2 24 | — | -698.3% | ||
| Q1 24 | — | -415.3% |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.24 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.29 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $45.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $15.3M |
| Total Assets | $140.4M | $50.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $45.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | — | $32.4M | ||
| Q1 25 | — | $41.8M | ||
| Q4 24 | — | $30.3M | ||
| Q3 24 | — | $36.6M | ||
| Q2 24 | — | $41.4M | ||
| Q1 24 | — | $47.2M |
| Q4 25 | $80.0M | $15.3M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | — | $34.3M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $46.1M |
| Q4 25 | $140.4M | $50.2M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $48.2M | ||
| Q4 24 | — | $36.9M | ||
| Q3 24 | — | $40.4M | ||
| Q2 24 | — | $44.8M | ||
| Q1 24 | — | $51.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-35.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-35.3M | ||
| Q3 25 | — | $-6.2M | ||
| Q2 25 | — | $-10.3M | ||
| Q1 25 | — | $-9.0M | ||
| Q4 24 | — | $-25.6M | ||
| Q3 24 | — | $-5.1M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-5.7M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
